
First Inhaled Gene Therapy for Lung Cancer Wins FDA FastâTrack Nod, Raising Hopes â and Questions
An inhaled gene therapy targeting lung cancer has shown promising early clinical efficacy and received FDA RMAT designation and fastâtrack status. The move accelerates regulatory review but leaves open critical questions about safety, durability, manufacturing and who will ultimately benefit.


















